Australia Cloning And Mutagenesis Market Size & Outlook
Australia cloning and mutagenesis market, 2018-2030 (US$M)
Related Markets
Australia cloning and mutagenesis market highlights
- The Australia cloning and mutagenesis market generated a revenue of USD 52.5 million in 2022 and is expected to reach USD 246.3 million by 2030.
- The Australia market is expected to grow at a CAGR of 21.3% from 2023 to 2030.
- In terms of segment, topo pcr cloning was the largest revenue generating technology in 2022.
- Site-Directed Mutagenesis is the most lucrative technology segment registering the fastest growth during the forecast period.
Cloning and mutagenesis market data book summary
| Market revenue in 2022 | USD 52.5 million |
| Market revenue in 2030 | USD 246.3 million |
| Growth rate | 21.3% (CAGR from 2022 to 2030) |
| Largest segment | Topo pcr cloning |
| Fastest growing segment | Site-Directed Mutagenesis |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis |
| Key market players worldwide | Agilent Technologies Inc, Thermo Fisher Scientific Inc, New England Biolabs, Takara Bio Inc, Merck KGaA, Promega, Bio-Rad Laboratories Inc, Danaher Corp, Assay Genie, Jena Bioscience, TransGen Biotech |
Other key industry trends
- In terms of revenue, Australia accounted for 2.3% of the global cloning and mutagenesis market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan cloning and mutagenesis market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 699.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cloning and Mutagenesis Market Scope
Cloning and Mutagenesis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia cloning and mutagenesis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cloning and mutagenesis market will help companies and investors design strategic landscapes.
Topo pcr cloning was the largest segment with a revenue share of 29.14% in 2022. Horizon Databook has segmented the Australia cloning and mutagenesis market based on topo pcr cloning, blunt end cloning, seamless cloning, site-directed mutagenesis covering the revenue growth of each sub-segment from 2018 to 2030.
- Australia Cloning and Mutagenesis Technology Outlook (Revenue, USD Million, 2018-2030)
- Topo PCR Cloning
- Blunt End Cloning
- Seamless Cloning
- Site-Directed Mutagenesis
- Others
- Australia Cloning and Mutagenesis Product Outlook (Revenue, USD Million, 2018-2030)
- Cloning Kits
- Mutagenesis Kits
- Others
- Australia Cloning and Mutagenesis End-user Outlook (Revenue, USD Million, 2018-2030)
- Biopharmaceutical & Pharmaceutical Companies
- CROs & CMOs
- Academic & Research Institutes
Reasons to subscribe to Australia cloning and mutagenesis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia cloning and mutagenesis market databook
-
Our clientele includes a mix of cloning and mutagenesis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia cloning and mutagenesis market, including forecasts for subscribers. This country databook contains high-level insights into Australia cloning and mutagenesis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia cloning mutagenesis market report size, by technology, 2018-2030 (US$M)
Australia Cloning and Mutagenesis Market Share, 2022 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
